rs622342 in
OCT1
SLC22A1
single nucleotide polymorphisms
type 2 diabetes mellitus
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
20 Jun 2020
20 Jun 2020
Historique:
received:
19
05
2020
revised:
14
06
2020
accepted:
16
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
Since the treatment outcome with oral anti-diabetics differs between individuals, the objective of this study is to evaluate the significance of rs622342 in Eighty-eight Lebanese individuals with T2DM received metformin/sulfonylurea combination therapy over 3 and 6 months. The clinical and biochemical characteristics were collected. Genotyping of rs622342 in The levels of fasting blood sugar (FBS) and glycated hemoglobin (HbA1c) showed a statistically significant reduction over 3 and 6 months of follow-up ( The combination of metformin/sulfonylurea therapy led to the maximum glycemic control in individuals with T2DM carrying AA or AC genotypes in
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Since the treatment outcome with oral anti-diabetics differs between individuals, the objective of this study is to evaluate the significance of rs622342 in
METHODS
METHODS
Eighty-eight Lebanese individuals with T2DM received metformin/sulfonylurea combination therapy over 3 and 6 months. The clinical and biochemical characteristics were collected. Genotyping of rs622342 in
RESULTS
RESULTS
The levels of fasting blood sugar (FBS) and glycated hemoglobin (HbA1c) showed a statistically significant reduction over 3 and 6 months of follow-up (
CONCLUSION
CONCLUSIONS
The combination of metformin/sulfonylurea therapy led to the maximum glycemic control in individuals with T2DM carrying AA or AC genotypes in
Identifiants
pubmed: 32575674
pii: jpm10020053
doi: 10.3390/jpm10020053
pmc: PMC7354490
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Clin Pharmacol. 2014 Apr;70(4):421-8
pubmed: 24442125
Eur J Clin Pharmacol. 2011 Aug;67(8):797-801
pubmed: 21336994
J Drug Assess. 2019 Jun 05;8(1):115-121
pubmed: 31231590
Diabetologia. 2017 Sep;60(9):1586-1593
pubmed: 28770321
Pharmacogenomics. 2018 Apr;19(6):577-587
pubmed: 29580198
BMC Med Genet. 2017 Jun 6;18(1):64
pubmed: 28587604
Physiology (Bethesda). 2018 Mar 1;33(2):138-150
pubmed: 29412061
Wien Klin Wochenschr. 2019 May;131(Suppl 1):6-15
pubmed: 30980151
J Pharm Sci. 2017 Sep;106(9):2695-2703
pubmed: 28435143
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
J Clin Pharm Ther. 2018 Dec;43(6):768-774
pubmed: 29802808
Ann Intern Med. 2018 Jan 16;168(2):JC8
pubmed: 29335720
J Diabetes Investig. 2018 Sep;9(5):1144-1152
pubmed: 29328551
Curr Diab Rep. 2019 Jul 8;19(8):54
pubmed: 31286271
Diabetes Ther. 2018 Oct;9(5):1945-1958
pubmed: 30121726
Diabet Med. 2019 Nov 10;:
pubmed: 31709648
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Lancet. 2019 Oct 26;394(10208):1483-1485
pubmed: 31542294
J Clin Pharmacol. 2019 Oct;59(10):1384-1390
pubmed: 31012983
J Pharm Sci. 2017 Sep;106(9):2245-2250
pubmed: 28495567
Regul Toxicol Pharmacol. 2018 Feb;92:324-332
pubmed: 29291990
Biomed Rep. 2019 May;10(5):283-295
pubmed: 31086662
Clin Pharmacol Ther. 2010 Jan;87(1):52-6
pubmed: 19794412
J Pharmacol Exp Ther. 2010 Oct;335(1):42-50
pubmed: 20639304
Drug Metab Pharmacokinet. 2020 Feb;35(1):160-164
pubmed: 31974043
Clin Exp Med. 2015 Nov;15(4):511-7
pubmed: 25492374
Pharmacogenomics J. 2009 Aug;9(4):242-7
pubmed: 19381165